Current Trends on Glomerulosclerosis Regression.

Area of Science:

• Nephrology
• Cardiovascular Research
• Endocrinology

Background:

• The renin-angiotensin system (RAS) is crucial in regulating blood pressure and is implicated in hypertension and end-organ damage.
• Angiotensin l converting enzyme inhibitors and angiotensin II type 1 receptor antagonists demonstrate protective effects on the kidney.
• Emerging evidence suggests non-hemodynamic roles for Angiotensin II in progressive renal disease.

Purpose of the Study:

• To explore the intricate interactions within the renin-angiotensin-aldosterone system (RAAS).
• To investigate the link between the RAAS and plasminogen activator-inhibitor-1 (PAI-1) in renal pathogenesis.
• To elucidate the significance of these interactions in progressive renal disease and renal sclerosis.

Main Methods:

• Review of existing literature on the renin-angiotensin system's role in renal disease.
• Analysis of studies investigating the effects of ACE inhibitors and ARBs on renal outcomes.
• Exploration of the connection between RAS components, PAI-1, aldosterone, and bradykinin.

Main Results:

• Angiotensin l converting enzyme inhibitors offer superior renal protection compared to other antihypertensives.
• Angiotensin II type 1 receptor antagonists can improve or reverse glomerulosclerosis in animal models.
• The RAS is linked to PAI-1 induction, potentially mediating thrombosis and fibrosis.

Conclusions:

• Inhibition of the RAS is beneficial for mitigating renal fibrosis.
• Angiotensin II exerts significant non-hemodynamic effects on renal function and structure.
• Understanding RAAS-PAI-1 interactions is vital for managing progressive renal disease and renal sclerosis.